BACKGROUND: Angiogenesis plays an important role in endometrial carcinogenesis. We reviewed our experience with the anti-VEGF monoclonal antibody bevacizumab for the treatment of recurrent uterine neoplasms. PATIENTS AND METHODS: A retrospective analysis of women with recurrent uterine neoplasms treated with bevacizumab was performed. RESULTS: A total of 11 patients were identified, 9 with epithelial endometrial carcinomas and 2 with leiomyosarcomas. All patients had multi-site disease and were heavily pretreated with a median of 3 prior chemotherapy regimens. All received bevacizumab combination therapy which was well-tolerated. Two patients had partial responses, 3 had stable disease, while 5 patients progressed. One subject was not assessable for response. The median progression-free interval was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit (PR or SD). CONCLUSION: Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma.
BACKGROUND: Angiogenesis plays an important role in endometrial carcinogenesis. We reviewed our experience with the anti-VEGF monoclonal antibody bevacizumab for the treatment of recurrent uterine neoplasms. PATIENTS AND METHODS: A retrospective analysis of women with recurrent uterine neoplasms treated with bevacizumab was performed. RESULTS: A total of 11 patients were identified, 9 with epithelial endometrial carcinomas and 2 with leiomyosarcomas. All patients had multi-site disease and were heavily pretreated with a median of 3 prior chemotherapy regimens. All received bevacizumab combination therapy which was well-tolerated. Two patients had partial responses, 3 had stable disease, while 5 patients progressed. One subject was not assessable for response. The median progression-free interval was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit (PR or SD). CONCLUSION:Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma.
Authors: Jeong-Won Lee; Rebecca L Stone; Sun Joo Lee; Eun Ji Nam; Ju-Won Roh; Alpa M Nick; Hee-Dong Han; Mian M K Shahzad; Hye-Sun Kim; Lingegowda S Mangala; Nicholas B Jennings; Shenlan Mao; John Gooya; Dowdy Jackson; Robert L Coleman; Anil K Sood Journal: Clin Cancer Res Date: 2010-04-13 Impact factor: 12.531
Authors: Susana M Campos; William E Brady; Katherine M Moxley; Roisin E O'Cearbhaill; Paula S Lee; Paul A DiSilvestro; Jacob Rotmensch; Peter G Rose; Premal H Thaker; David M O'Malley; Parviz Hanjani; Rosemary E Zuna; Martee L Hensley Journal: Gynecol Oncol Date: 2014-03-01 Impact factor: 5.482